about
Identification of semaphorin 5A interacting protein by applying apriori knowledge and peptide complementarity related to protein evolution and structure.Identification of functional cell adhesion molecules with a potential role in metastasis by a combination of in vivo phage display and in silico analysis.A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047.Prediction of epigenetically regulated genes in breast cancer cell linesA cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesisChemokines in tumor angiogenesis and metastasisSemaphorin 5A mediated cellular navigation: connecting nervous system and cancerIdentification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis.Subtype and pathway specific responses to anticancer compounds in breast cancer.The consensus molecular subtypes of colorectal cancerGenomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic CharacteristicsA colorectal cancer classification system that associates cellular phenotype and responses to therapyCXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasionSmall interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion.Reconciliation of classification systems defining molecular subtypes of colorectal cancer: interrelationships and clinical implications.Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?Molecular subtypes in cancers of the gastrointestinal tract.Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.A Novel Statistical Method to Diagnose, Quantify and Correct Batch Effects in Genomic Studies.A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocPatient-derived organoids model treatment response of metastatic gastrointestinal cancers.polyClustR: defining communities of reconciled cancer subtypes with biological and prognostic significance.Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancerMicroenvironmental niche divergence shapes BRCA1-dysregulated ovarian cancer morphological plasticityA seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trialContext matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trialsInter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinomaEnhanced expression and shedding of receptor activator of NF-kappaB ligand during tumor-bone interaction potentiates mammary tumor-induced osteolysisReply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response
P50
Q30375843-8F7C12C4-9C32-4D71-AE02-763A453AE7D4Q33281296-6D955FC9-B6D9-4039-9DFD-DB15546EB14BQ33517982-B91D84FF-F833-412C-8CE6-28F1C0EF577CQ33595315-0DB6CB97-EF72-42EF-B839-FB41EEC7483AQ33966547-352A615A-8A36-43EE-A0C0-7F723182BD3DQ34512415-CBB45FD7-B0D6-4046-A697-18A52C126102Q34540743-28AF53D5-72D2-4463-8186-7702358C6ABDQ34663792-45A9631D-C2DD-45E0-88D0-4C028A06D344Q34731699-1B836CD7-A6FB-4B71-B80D-559D6059555CQ35779241-8AAA2AFE-BC9F-4283-9948-3D1F31F1D03FQ36258187-8D93E73A-2D4F-4731-8397-B4A10FF07AD4Q36438357-A662537A-776D-41AF-9B43-BEA674DF57C4Q37097257-040632AF-1955-4E61-AAE1-8E08822B8A17Q37175913-047D51A4-C124-49A4-B58D-1406319A843FQ37228501-AB0BFCD1-4571-4194-8DAD-1FDC539D8089Q37480197-C75FD812-B791-433F-9AC9-FEE085107585Q37641522-9E096157-E177-44AD-9354-B27A0CADFB42Q38956018-08961BF8-7F84-462C-97CA-34DD66316A7EQ39235977-1F21B2A0-303F-44CD-97D4-87151A6B8D44Q39911589-BA96E131-6C5C-4648-9509-701E2B0D884AQ41535701-40A621F5-37CB-4300-8FCE-9AECB6C4284DQ41556432-EC55EB5B-07EE-4E80-92F7-5AD0E0FFD1B9Q53707065-AC1863C4-F19A-4EF0-A51B-7E5F3A1C48F8Q55311987-EEED6A61-3BF9-4BEA-8F73-A608DB965BB8Q57799070-4A2E1303-0A57-4B30-9C24-CF9B68FEA0B1Q58698836-7B274DE8-A0CD-4642-A872-80F43BC2121DQ60934019-99E93739-D03C-4B75-B5CC-374301ABAC2BQ64107999-5E2D7B4B-46BF-445B-9D34-A420421C0DFEQ64112228-70D40A69-6C5E-400D-A106-1F2AEF004CC4Q84204534-DA2954E7-CA8C-426C-826B-1164F5E7097AQ85920183-3F8A06B3-4976-4A01-BF5D-C911C41BDDA3
P50
description
researcher, ORCID id # 0000-0001-8485-5150
@en
wetenschapper
@nl
name
Anguraj Sadanandam
@ast
Anguraj Sadanandam
@en
Anguraj Sadanandam
@es
Anguraj Sadanandam
@nl
type
label
Anguraj Sadanandam
@ast
Anguraj Sadanandam
@en
Anguraj Sadanandam
@es
Anguraj Sadanandam
@nl
prefLabel
Anguraj Sadanandam
@ast
Anguraj Sadanandam
@en
Anguraj Sadanandam
@es
Anguraj Sadanandam
@nl
P108
P106
P1153
6601970735
P31
P496
0000-0001-8485-5150